Attached files
file | filename |
---|---|
8-K - CURRENT REPORT - Humacyte, Inc. | ea141748-8k_alphahealth.htm |
EX-99.1 - PRESS RELEASE, DATED MAY 22, 2021 - Humacyte, Inc. | ea141748ex99-1_alphahealth.htm |
Exhibit 99.2
Humacyte Receives 2021 Life Sciences Award from Triangle Business Journal
Company recognized for its innovative contributions to the life sciences industry in North Carolina
Durham, N.C. – May 26, 2021 – Humacyte, Inc., a clinical-stage biotechnology platform company developing universally implantable bioengineered human tissue at commercial scale, today announced that the company has received a 2021 Life Sciences Award from the Triangle Business Journal.
The annual Triangle Business Journal awards program honors individuals and organizations in the Raleigh-Durham area that are blazing trails and breaking ground in the life sciences industry. Winners were honored at a virtual award ceremony on May 20, 2021.
“We are honored to receive the Triangle Business Journal's Life Sciences award and be named among a group of extraordinary organizations in North Carolina that are transforming the life sciences industry,” said Laura Niklason, M.D., Ph.D., Chief Executive Officer of Humacyte. “This award highlights Humacyte’s dedication to becoming a leader in regenerative medicine by pioneering the development of our first-in-class bioengineered human tissue, made possible by our talented team and the support of a thriving local life sciences ecosystem.”
Humacyte develops and manufactures acellular tissues to treat a wide range of diseases, injuries and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Founded in 2004 by Drs. Niklason, Juliana Blum, and Shannon Dahl, the company has assembled a seasoned team of more than 130 scientists based in an 83,000 square-foot bioprocessing facility and corporate office space in Durham.
Information on the Triangle Business Journal’s Life Sciences awards program and the complete list of winners can be found on the Triangle Business Journal’s website at: https://www.bizjournals.com/triangle/news/2021/05/21/2021-life-sciences-awards-humacyte.html?s=print.
On February 17, 2021, Alpha Healthcare Acquisition Corp. (Nasdaq: AHAC) (“AHAC”), a special purpose acquisition company, and Humacyte announced the execution of a definitive business combination agreement along with a fully committed $175 million PIPE financing agreement.
About Humacyte
Humacyte, Inc., is developing a disruptive biotechnology platform to deliver universally implantable bioengineered human tissues and organs designed to improve the lives of patients and transform the practice of medicine. The Company develops and manufactures acellular tissues to treat a wide range of diseases, injuries, and chronic conditions. Humacyte’s initial opportunity, a portfolio of human acellular vessels (HAVs), is currently in late-stage clinical trials targeting multiple vascular applications, including vascular trauma repair, arteriovenous access for hemodialysis, and peripheral arterial disease. Pre-clinical development is also underway in coronary artery bypass grafts, pediatric heart surgery, treatment of type 1 diabetes, and multiple novel cell and tissue applications. Humacyte’s HAVs were the first product to receive the FDA’s Regenerative Medicine Advanced Therapy (RMAT) expedited review designation and received priority designation for the treatment of vascular trauma by the U.S. Secretary of Defense. For more information, visit www.Humacyte.com.
About
Alpha Healthcare Acquisition Corp.
Alpha Healthcare Acquisition Corp. (ticker: AHAC) is a special purpose acquisition company formed for the purpose of effecting a
business combination with one or more businesses in the healthcare sector (“AHAC”). The company was founded by Mr. Rajiv
Shukla who has two decades of buyouts, investments, and operations experience in the healthcare industry. Mr. Shukla previously
served as Chairman and Chief Executive Officer of Constellation Alpha Capital Corp., a Nasdaq-listed special purpose acquisition
company, that merged with DermTech, Inc. (ticker: DMTK) in August 2019. On February 17, 2021, AHAC announced a definitive agreement
to merge with Humacyte, Inc., along with a concurrent fully committed PIPE placement of $175 million of AHAC common shares at a price
of $10.00 per share.
Important
Information About the Merger and Where to Find It
A full description of the terms of the business combination is provided in a registration statement on Form S-4 filed with the SEC
by AHAC that includes a prospectus with respect to the Combined Company’s securities to be issued in connection with the business
combination and a proxy statement with respect to the shareholder meeting of AHAC to vote on the business combination. AHAC urges its
investors, shareholders, and other interested persons to read the preliminary proxy statement/ prospectus as well as other documents
filed with the SEC because these documents will contain important information about AHAC, Humacyte and the business combination. After
the registration statement is declared effective, the definitive proxy statement/prospectus included in the registration statement will
be mailed to shareholders of AHAC as of a record date to be established for voting on the proposed business combination. Shareholders
will also be able to obtain a copy of the Form S-4, including the proxy statement/prospectus, and other documents filed with the SEC
without charge, by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary, 1177 Avenue of the Americas, 5th Floor,
New York, New York 10036. The preliminary and definitive proxy statement/prospectus to be included in the registration statement,
can also be obtained, without charge, at the SEC’s website (www.sec.gov).
Participants
in the Solicitation
AHAC and Humacyte and their respective directors and executive officers may be considered participants in the solicitation of proxies
with respect to the proposed business combination described in this press release under the rules of the SEC. Information about the directors
and executive officers of AHAC is set forth in AHAC’s final prospectus filed with the SEC pursuant to Rule 424(b) of the Securities
Act of 1933, as amended (the “Securities Act”) on September 17, 2020, and is available free of charge at the SEC’s
website at www.sec.gov or by directing a request to: Alpha Healthcare Acquisition Corp., Attn: Secretary, 1177 Avenue of the Americas,
5th Floor, New York, New York 10036. Information regarding the persons who may, under the rules of the SEC,
be deemed participants in the solicitation of the AHAC shareholders in connection with the proposed business combination will be set
forth in the registration statement containing the proxy statement/prospectus for the proposed business combination. These documents
can be obtained free of charge from the sources indicated above.
2
Forward-Looking
Statements
This press release contains forward-looking statements that are based on beliefs and assumptions and on information currently available.
In some cases, you can identify forward-looking statements by the following words: “may,” “will,” “could,”
“would,” “should,” “expect,” “intend,” “plan,” “anticipate,”
“believe,” “estimate,” “predict,” “project,” “potential,” “continue,”
“ongoing” or the negative of these terms or other comparable terminology, although not all forward-looking statements contain
these words. These statements involve risks, uncertainties and other factors that may cause actual results, levels of activity, performance
or achievements to be materially different from the information expressed or implied by these forward-looking statements. Although we
believe that we have a reasonable basis for each forward-looking statement contained in this press release, we caution you that these
statements are based on a combination of facts and factors currently known by us and our projections of the future, about which we cannot
be certain. Forward-looking statements in this press release include, but are not limited to, statements regarding the initiation, timing,
progress, and results of our clinical trials; the anticipated characteristics and performance of our HAVs, our ability to successfully
complete, clinical trials for our HAVs; the anticipated benefits of our HAVs relative to existing alternatives; the commercialization
of our HAVs and our ability to manufacture at commercial scale; the implementation of our business model, strategic plans for our business;
the scope of protection we are able to establish and maintain for intellectual property rights covering our HAVs and related technology;
the timing or likelihood of regulatory filings and approvals; timing, scope, and rate of reimbursement for our HAVs; our estimated available
market opportunity; the proposed business combination, including the timing and structure of the business combination, the proceeds of
the business combination, and the benefits of the business combination. We cannot assure you that the forward-looking statements in this
press release will prove to be accurate. These forward-looking statements are subject to a number of significant risks and uncertainties
that could cause actual results to differ materially from expected results, including, among others, the ability to complete the business
combination due to the failure to obtain approval from AHAC’s shareholders or satisfy other closing conditions in the Business
Combination Agreement, the occurrence of any event that could give rise to the termination of the Business Combination Agreement, the
ability to recognize the anticipated benefits of the business combination, the outcome of any legal proceedings that may be instituted
against AHAC or Humacyte following announcement of the proposed business combination and related transactions, the impact of COVID-19
on Humacyte’s business and/or the ability of the parties to complete the business combination, the ability to obtain or maintain
the listing AHAC’s common stock on Nasdaq following the proposed business combination, costs related to the proposed business combination,
changes in applicable laws or regulations, the possibility that AHAC or Humacyte may be adversely affected by other economic, business,
and/or competitive factors, and other risks and uncertainties, including those included under the header “Risk Factors” in
the registration statement on Form S-4 filed by AHAC with the SEC and those included under the header “Risk Factors” in the
final prospectus of AHAC related to its initial public offering. Most of these factors are outside of AHAC’s and Humacyte’s
control and are difficult to predict. Furthermore, if the forward-looking statements prove to be inaccurate, the inaccuracy may be material.
In light of the significant uncertainties in these forward-looking statements, you should not regard these statements as a representation
or warranty by us or any other person that we will achieve our objectives and plans in any specified time frame, or at all. The forward-looking
statements in this press release represent our views as of the date of this press release. We anticipate that subsequent events and developments
will cause our views to change. However, while we may elect to update these forward-looking statements at some point in the future, we
have no current intention of doing so except to the extent required by applicable law. You should, therefore, not rely on these forward-looking
statements as representing our views as of any date subsequent to the date of this press release.
Non-Solicitation
This press release is not a proxy statement or solicitation of a proxy, consent, or authorization with respect to any securities
or in respect of the proposed business combination and shall not constitute an offer to sell or a solicitation of an offer to buy any
securities nor shall there be any sale of securities in any state or jurisdiction in which such offer, solicitation, or sale would be
unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. No offer of securities shall
be made except by means of a prospectus meeting the requirements of the Securities Act.
###
Humacyte Investor Contact:
Josh Rappaport
Josh.Rappaport@sternir.com
Humacyte Media Contacts:
Juliana Blum
EVP, Corporate Development
blum@humacyte.com
Heather Anderson
handerson@6degreespr.com
3